Pilates for lungs: new study tests exercise program for COPD patients
NCT ID NCT07267858
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether an 8-week Clinical Pilates program can improve lung function, chest mobility, motor performance, sleep, and quality of life in 38 people with mild (Gold A) COPD. Participants will attend two 60-minute sessions per week using soft balls and elastic bands. The goal is to see if this gentle exercise approach can help manage symptoms and improve daily living.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Clinical Pilates exercise programme
- What this could lead to
- If it works, this could offer a simple, drug-free way to help people with mild COPD breathe easier, move better, and sleep more soundly.
- What could go wrong
- This is a small, early-stage study with only 38 participants, so results may not apply to everyone with COPD. The program requires regular attendance, and benefits may vary.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
38 people
The number who actually took part.
- Started
-
Nov 2024
- Expected to finish
-
Jul 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
40 to 80 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Anyone diagnosed with COPD at GOLD stage A, duly identified in SClínico, registered with the USF and residing in the geographical area covered by the Guimarães UCC, whose participation is validated by their family doctor. Inclusion in the study implies participation in at least 60% of the programme sessions, namely 10. Exclusion Criteria: * People with a history of exacerbation of the disease less than 4 weeks ago, as the guidelines of the European Respiratory Society and the American Thoracic Society (2017) make a conditional recommendation on pulmonary rehabilitation after exacerbation and recommend waiting at least 3 weeks, severe osteoarticular limitation that prevents physical exercise, psychiatric illness or severe cognitive dysfunction, unstable comorbidities such as unstable ischaemic disease or decompensated heart failure, and exercise-induced hypoxemia refractory to oxygen administration.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COPD (chronic obstructive pulmonary disease) are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Unidade de Cuidados na Comunidade de Guimarães
Guimarães, 4800, Portugal
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Patient's own airway stem cells repair damaged lungs in COPD?
- Six biologics put to the test in Real-World asthma and COPD care
- Can a breathing routine ease COPD breathlessness?
- Switching to a nebulizer may help COPD patients who get no relief from inhalers
- Can extra oxygen during rehab change how COPD patients breathe?
- AI chest X-Rays could catch hidden lung disease in zambia